104 related articles for article (PubMed ID: 21663500)
1. Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy.
Luminari S; Cesaretti M; Tomasello C; Guida A; Bagni B; Merli F; Postiglione R; Mangone L; Versari A; Re F; De Lisi V; Ruffini L; Ferretti S; Cuneo A; Federico M
Leuk Lymphoma; 2011 Sep; 52(9):1689-96. PubMed ID: 21663500
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
Sickinger MT; von Tresckow B; Kobe C; Engert A; Borchmann P; Skoetz N
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010533. PubMed ID: 25572491
[TBL] [Abstract][Full Text] [Related]
3. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
[TBL] [Abstract][Full Text] [Related]
4. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
5. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
Gallamini A; Hutchings M; Rigacci L; Specht L; Merli F; Hansen M; Patti C; Loft A; Di Raimondo F; D'Amore F; Biggi A; Vitolo U; Stelitano C; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A
J Clin Oncol; 2007 Aug; 25(24):3746-52. PubMed ID: 17646666
[TBL] [Abstract][Full Text] [Related]
6. Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement.
El-Galaly TC; Hutchings M; Mylam KJ; Brown Pde N; Bukh A; Johnsen HE; Kamper P; Loft A; Iyer V; Gormsen LC; Nielsen AL; Bøgsted M; d'Amore F
Leuk Lymphoma; 2014 Oct; 55(10):2349-55. PubMed ID: 24354682
[TBL] [Abstract][Full Text] [Related]
7. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
[TBL] [Abstract][Full Text] [Related]
8. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
9. Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era.
Richardson SE; Sudak J; Warbey V; Ramsay A; McNamara CJ
Leuk Lymphoma; 2012 Mar; 53(3):381-5. PubMed ID: 21877882
[TBL] [Abstract][Full Text] [Related]
10. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
11. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
12. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Pretreatment Radiomic Features of 18F-FDG PET in Patients With Hodgkin Lymphoma.
Lue KH; Wu YF; Liu SH; Hsieh TC; Chuang KS; Lin HH; Chen YH
Clin Nucl Med; 2019 Oct; 44(10):e559-e565. PubMed ID: 31306204
[TBL] [Abstract][Full Text] [Related]
14. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
15. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
16. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
17. Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma.
Iltis A; Eder V; Blasco H; Colombat P; Sénécal D
Acta Haematol; 2015; 133(2):172-8. PubMed ID: 25301496
[TBL] [Abstract][Full Text] [Related]
18. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi.
Rigacci L; Vitolo U; Nassi L; Merli F; Gallamini A; Pregno P; Alvarez I; Salvi F; Sancetta R; Castagnoli A; Versari A; Biggi A; Gregianin M; Pelosi E; Chisesi T; Bosi A; Levis A;
Ann Hematol; 2007 Dec; 86(12):897-903. PubMed ID: 17701410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
